Loading
NASDAQHealthcareMedical - Devices
Latest quote
$77.87
−$1.13 · -1.43%
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
Previous close
$77.87
−$1.13 · -1.43%
Regular session · ET · Market data may be delayed.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
Day range
Current $77.87
52-week range
Current $77.87
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
87
Deep Value
Sentiment
78
Bullish
Risk
71
High Risk
Momentum
25
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
Day range
Current $77.87
52-week range
Current $77.87
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 605.49M USD | 441.54M USD | 241.62M USD | 93.46M USD | 30.26M USD |
| Cost of goods sold | 242.69M USD | 179.46M USD | 87.53M USD | 28.19M USD | 9.1M USD |
| Gross profit | 362.81M USD | 262.08M USD | 154.09M USD | 65.27M USD | 21.16M USD |
| Research and development | 69.06M USD | 55.97M USD | 63.27M USD | 26.81M USD | 22.3M USD |
| Selling, general, and administrative | 185.17M USD | 168.62M USD | 119.55M USD | 69.9M USD | 38.28M USD |
| Operating expenses | 254.22M USD | 224.59M USD | 182.82M USD | 96.71M USD | 60.59M USD |
| Interest income | — | — | 12.5M USD | 900K USD | — |
| Interest expense | 13.78M USD | 14.41M USD | 10.79M USD | 3.73M USD | 3.87M USD |
| Depreciation and amortization | 27.19M USD | 19.76M USD | 8.18M USD | 3.48M USD | 1.82M USD |
| Operating income | 108.58M USD | 37.5M USD | −28.73M USD | −31.44M USD | −39.43M USD |
| Net income | 190.29M USD | 35.46M USD | −25.03M USD | −36.23M USD | −44.22M USD |
Company facts updated Oct 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$99.75
28.10% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI88.39M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM71.09M0.09%78.74B USD0.19%$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB64.06M0.03%185.3B USD0.03%$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK36.7M0.08%44.7B USD0.05%$344.74+1.22%
Vanguard Extended Market ETFVXF34.1M0.04%95.4B USD0.05%$235+0.80%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM25.25M0.16%15.84B USD0.03%$53.45+0.17%
iShares Russell 2000 Growth ETFIWO25.05M0.18%13.92B USD0.24%$356.78+0.94%
YieldMax Ultra Option Income Strategy ETFULTY22.47M3.21%700.36M USD1.40%$25.52+1.15%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMiShares Russell 2000 Growth ETFIWOYieldMax Ultra Option Income Strategy ETFULTYAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
